primary antibodies against cyclin-dependent kinase 1  (Thermo Fisher)

Journal: Drug Design, Development and Therapy

Article Title: Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway

doi: 10.2147/DDDT.S74197

Figure Lengend Snippet: ALS modulates the expression of CDK2, CDC2, cyclin B1, p21 Waf1/Cip1, and p53 in U-2 OS and MG-63 cells. Notes: U-2 OS and MG-63 cells were treated with ALS at 0.1, 1, and 5 μM for 24 hours and then subjected to Western blotting assay. ( A ) Representative blots of CDK2, CDC2, cyclin B1, p21 Waf1/Cip1, and p53 and ( B ) bar graphs showing the relative expression levels of CDK2, CDC2, cyclin B1, p21 Waf1/Cip1, and p53 in U-2 OS and MG-63 cells. β-actin was used as the internal control. Data are the mean ± SD of three independent experiments. * P <0.05; ** P <0.01; and *** P <0.001 by one-way ANOVA. Abbreviations: ALS, alisertib; SD, standard deviation; ANOVA, analysis of variance; CDK, cyclin-dependent kinase; OS, osteosarcoma.

Article Snippet: Primary antibodies against human p53, p21 Waf1/Cip1, cyclin B1, cyclin-dependent kinase 1 (CDK1/CDC2/CDKN1), CDK2, PUMA, Bax, Bcl-2, cytochrome c, cleave caspase-3 and 9, beclin 1, Sirt1, nuclear factor-erythroid-2-related factor 2 (Nrf2), microtubule-associated protein 1A/1B-light chain 3 (LC3-I), LC3-II, phosphatase and tensin homolog (PTEN) PI3K, phosphorylated PI3K (p-PI3K/p85 at Tyr458), AMPK, p-AMPK at Thr172, p38 mitogen-activated protein kinase (MAPK), p-p38 MAPK at Thr180/Tyr182, Akt, p-Akt at Ser473, mTOR, p-mTOR at Ser2448, and EMT antibody sampler kit (No: #9782) were all purchased from Cell Signaling Technology Inc. (Beverly, MA, USA).

Techniques: Expressing, Western Blot, Standard Deviation

Journal: Oncology Letters

Article Title: The natural sweetener metabolite steviol inhibits the proliferation of human osteosarcoma U2OS cell line

doi: 10.3892/ol.2018.7962

Figure Lengend Snippet: Expression of cell cycle-associated proteins regulated by steviol. (A) p21, p53, Cyclin D1, Cyclin E, CDK2. (B) Relative expression levels of cell cycle-associated proteins, calculated based on densitometric analysis. β-actin was used as an internal control. *P<0.05 and **P<0.01 vs. untreated cells. p21, cyclin-dependent kinase inhibitor 1; p53, tumor protein 53; CDK2, cyclin-dependent kinase 2.

Article Snippet: All antibodies were purchased from Cell Signaling Technologies, Inc. (Danvers, MA, USA): Primary antibodies against cyclin-dependent kinase inhibitor 1 rabbit mAb (p21, 21 kDa; cat. no. 2947S; 1:1,000 dilution), tumor protein 53 rabbit mAb (p53, 53 kDa; cat. no. 2527S; 1:1,000 dilution), Cyclin D1 rabbit mAb (36 kDa; cat. no. 2978T; 1:1,000 dilution), Cyclin E rabbit mAb (48 kDa; cat. no. 20808S; 1:1,000 dilution), cyclin-dependent kinase 2 (CDK2; cat. no. 78B2) rabbit mAb (33 kDa; cat. no. 2546S; 1:1,000 dilution), B-cell lymphoma 2 (Bcl-2) mouse mAb (26 kDa; cat. no. 15071S; 1:1,000 dilution), Bcl-2 X associated protein (Bax) rabbit mAb (20 kDa; cat. no. 5023S; 1:1,000 dilution), Caspase 3 rabbit mAb (35 kDa; cat. no. 9665S; 1:1,000 dilution), Survivin rabbit mAb (16 kDa,; cat. no. 2808S; 1:1,000 dilution), β-Actin rabbit mAb (45 kDa; cat. no. 4970S; 1:1,000 dilution) and horseradish peroxidase-conjugated secondary antibodies (anti-rabbit IgG, HRP-linked antibody; cat. no. 7074; anti-mouse IgG, HRP-linked antibody; cat. no. 7076).

Techniques: Expressing, Control